Valganciclovirisamono-valylesterprodrugofganciclovirthatisorallybioavailableandiswellabsorbedinthegastrointestinalsystem.Valganciclovirisanantiviralcompoundthat,likeganciclovir,isananalogof2’-deoxy-guanosinethatisincorporatedintoDNAbyviralDNApolymerase,preventingchainelongation.Thiscompoundisusedtotreatcytomegalovirus(CMV)innewbornsandadultsandmayalsoexhibitbenefitinthetreatmentofKaposisarcomaflares.
| CasNo. | 175865-59-5 |
|---|---|
| Purity | ≥98% |
| Formula | C14H22N6O5•HCl |
| FormulaWt. | 354.36 |
| IUPACName | [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl](2S)-2-amino-3-methylbutanoate;hydrochloride |
| Appearance | Whitetooffwhitepowder |
| StoreTemp | Ambient |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | V0244InfoSheetPDF |
|---|
StronatiM,LombardiG,GarofoliF,etal.Pharmacokinetics,pharmacodynamicsandclinicaluseofvalganciclovirinnewbornswithsymptomaticcongenitalcytomegalovirusinfection.CurrDrugMetab.2013Feb;14(2):208-15.PMID:22935067.
IwasenkoJM,ScottGM,RawlinsonWD,etal.Successfulvalganciclovirtreatmentofpost-transplantcytomegalovirusinfectioninthepresenceofUL97mutationN597D.JMedVirol.2009Mar;81(3):507-10.PMID:19152402.
PantanowitzL,FrühK,MarconiS,etal.Pathologyofrituximab-inducedKaposisarcomaflare.BMCClinPathol.2008Jul23;8:7.PMID:18651955.
